Andrew Chadeayne is the founder and CEO of the psychedelic pharma company CaaMTech located in Issaquah, Washington.
Dr. Chadeayne earned his Bachelor of Arts degree in neuropsychology and chemistry from Princeton University in 2001 and his Ph.D. in chemistry from Cornell University in 2006. He went on to study law at The George Washington University Law School, where he received his J.D. in patent law in 2011. Upon graduating, Dr. Chadeayne was awarded the American Bar Association’s Award for Excellence in Intellectual Property.
Before founding CaaMTech in January 2019, Dr. Chadeayne was Chief Innovations Officer for cannabis technology firm Ebbu. He exited Ebbu in December 2018 when they were purchased by Canopy Growth Corporation for $429 million.
While at the helm of CaaMTech, Dr. Chadeayne and his research teams have authored several papers on the crystal structure of tryptamine compounds including 4-AcO-DMT (psilacetin), MPT, norpsilocin, and 5-MeO-DALT.1–8 The characterization of these compounds is critical for developing safe and effective psychedelic drugs.
Barb is the former Editor and one of the founders of Psychedelic Science Review. She is currently a contributing writer. Her goal is making accurate and concise psychedelic science research assessable so that researchers and private citizens can make informed decisions.
Support Scientific Progress
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.
